Patents
Literature
108 results about "Mucoadhesion" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bioadhesion is the mechanism by which two biological materials are held together by interfacial forces. When relating this mechanism to the pharmaceutical sciences, mucoadhesion describes the attractive forces between a biological material and mucus or mucous membrane. Mucous membranes adhere to epithelial surfaces such as the gastrointestinal tract (GI-tract), the vagina, the lung, the eye, etc. They are generally hydrophilic as they contain many hydrogen macromolecules due to the large amount of water (approximately 95%) within its composition. However, mucin also contains glycoproteins that enable the formation of a gel-like substance. Understanding the hydrophilic bonding and adhesion mechanisms of mucus to biological material is of utmost importance in order to produce the most efficient applications. For example, in drug delivery systems, the mucus layer must be penetrated in order to effectively transport micro- or nanosized drug particles into the body.
Probiotic-polyphenol nanoparticle colon-targeted co-delivery system as well as preparation method and application thereof
PendingCN120899768AAntibacterial agentsHydroxy compound active ingredientsBiotechnologyClostridium difficile infections
The invention discloses a probiotic-polyphenol nanoparticle colon-targeted co-delivery system as well as a preparation method and application thereof, and belongs to the field of biological medicines. The FCPs and hyaluronic acid (HA) are combined through non-covalent interaction, so that the hydrogel has colon targeting property and mucosal adhesion at the same time, and delivery of probiotics is facilitated. The hydrogel (HF) based on polysaccharide has good biocompatibility, and can be used for effectively encapsulating the probiotics and the natural products. Then, the PDA-TH NPs and BA are incorporated into the polysaccharide chain network of HF, and finally the BA-HF-PDAT targeted co-delivery system is constructed. The BA (at) HF-PDAT targeted co-delivery system can protect BA from serious gastrointestinal stress, and is jointly assembled with PDT-TH NPs to realize dual slow release of thymol (Thy), so that the treatment effect of BA and Thy is improved, and the BA (at) HF-PDAT targeted co-delivery system contributes to treatment of clostridium difficile infection (CDI).
Owner:NORTHWEST A & F UNIV
Methods for treating treatment resistant depression
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.
Owner:ATAI THERAPEUTICS INC
Muco-adhesive, controlled release formulation of levodopa and / or esters of levodopa and uses thereof
The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
Owner:IMPAX LABORATORIES LLC
Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections
ActiveUS12459988B2Antibody mimetics/scaffoldsPeptide/protein ingredientsAnti-Influenza Virus AntibodyChimera Protein
The present application provides chimeric proteins comprising an antibody moiety that specifically binds to a component of an influenza virus or a variant thereof, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating an infection caused by an influenza virus or a variant thereof in an individual.
Owner:INVISISHIELD TECHNOLOGIES LTD
Enteric coating for targeting the duodenum
A system for targeted delivery of a medicament to the gastrointestinal tract (e.g., selectively to the duodenum) of a subject. The system includes a medicament, a mucoadhesive layer at least partially surrounding the medicament, and an enteric coating encasing the medicament and mucoadhesive layer. The enteric coating comprises a material degradable by a pH of the GI tract and a material digestible by a lipase. Also provided are method of making and using the system for targeted delivery of a medicament to the gastrointestinal tract. Also provided are a system for deploying a medicament-containing needle system using an expanding element. The system includes a medicament-containing needle system and an expanding element within a capsule. The capsule is initially coated with an enteric coating. As the enteric coating degrades the expanding element absorbs fluid that enters the capsule and expands to deploy the medicament-containing needle system from the capsule.
Owner:VERILY HEALTH INC
Muco-adhesive, controlled release formulation of levodopa and / or esters of levodopa and uses thereof
ActiveUS12491164B2Organic active ingredientsGranular deliveryImmediate releasePharmaceutical medicine
The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.
Owner:IMPAX LABORATORIES LLC
Muco-adhesive, controlled release formulations of levodopa and / or esters of levodopa and uses thereof
The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
Owner:IMPAX LABORATORIES LLC
Muco-adhesive, controlled release formulation of levodopa and / or esters of levodopa and uses thereof
The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.
Owner:IMPAX LABORATORIES LLC
Inhalation formulation of amoxicillin clavulanate
PCT designated stage expiredWO2025141531A1Dispersion deliveryAerosol deliverySide effectAntibiotic resistance
This invention provides a novel nebulization suspension comprising amoxicillin and clavulanate for the effective treatment of pneumonia. The formulation is specifically designed for pulmonary delivery, offering several advantages over traditional oral antibiotics. Key features include mucoadhesive properties that enhance drug retention 5 in the lungs, sustained release characteristics for prolonged therapeutic action, and potential biofilm disruption to combat antibiotic resistance. This localized delivery approach aims to minimize systemic side effects, improve treatment efficacy, and address the growing challenge of antibiotic resistance in pneumonia.
Owner:AODH LIFESCI PTE LTD
A functionalized tamarind seed polysaccharide and a preparation process thereof
PCT designated stageWO2026033304A1Organic active ingredientsCosmetic preparationsPolymer sciencePharmacy medicine
A functionalized tamarind seed polysaccharide, and a process for its preparation. In particular, said functionalized tamarind seed polysaccharide is a TSP having a selected functionalization degree and molecular weight, showing improved mucoadhesive properties, as well as stability and compatibility with pharmaceutical ingredients. Therefore, the invention also relates to a pharmaceutical composition, as well as a biomaterial, comprising said f-TSP.
Owner:FARMIGEA SPA
Compositions comprising chlorhexidine and a depigmenting complex
PCT designated stageWO2026047527A1Cosmetic preparationsToilet preparationsActive agentPhosphorylcholine
A complex consisting of lipoic acid or a salt thereof, a chelating agent such as a salt of ethylene diamine tetraacetic acid (EDTA) or analogous compounds and an ester of ascorbic acid with long-chain fatty acids, in particular ascorbyl palmitate inhibits the pigmentation of teeth induced by chlorhexidine and salts thereof. In addition to the depigmenting complex, the formulations of the invention, in the form of gels, mouthwashes, toothpastes or periodontal sprays, may contain other ingredients such as hyaluronic acid or hyaluronates, glycerophosphocholine, sweeteners, flavourings, buffering agents, viscosifying agents, mucoadhesive and filming agents, solvents, co-solvents, surfactants.
Owner:RICERFARMA
Orodispersible solid composition in the form of film for oral administration of thyroid hormones
PCT designated stageWO2025253253A1Organic active ingredientsSheet deliveryThyroid hormonesOral medication
Solid orodispersible compositions in the form of thin films for the oral administration of thyroid hormones are described, characterized by a high stability, and by the bioavailability of the active ingredient for oral absorption. The film compositions described are designed for rapid disintegration in the mouth, for sublingual administration, or to be held in the mouth for longer times before they disintegrate, but in any case without being mucoadhesive films. All the examples described are characterized by being thin and flexible and are suitable for administration even to patients who are not conscious, dysphagic or otherwise unable to swallow.
Owner:IBSA INSTITUT BIOCHIMIQUE SA
Liposome drug carrier with mucosal adhesion and its preparation method and application
ActiveCN116617405BImprove stabilityImprove adhesionOrganic active ingredientsSenses disorderEpitheliumCyclosporins
The application discloses a liposome drug carrier with mucosal adhesion, a preparation method and application thereof, and specifically, the drug carrier is DSPE-PEG-PBA, which can be used for loading cyclosporine A and crocin I, and the carrier of the application is used for loading cyclosporine A and crocin I. The liposome loaded with the two drugs has good stability and adhesion, can inhibit the side effect of cyclosporine A on the increase of ROS level, and has a wide application prospect in the treatment of inflammation and epithelial tissue damage.
Owner:SICHUAN UNIV
Bioadhesive film and methods of use thereof
A film and a method for use thereof such as for the administration of a biologically active agent or for therapy are provided. Specifically, a film, composed of a biodegradable material having a mucoadhesive surface comprising a plurality of mushroom-type structures is provided.
Owner:AZRIELI COLLEGE OF ENG JERUSALEM +1
Amoxicillin clavulanate nasal spray
PCT designated stage expiredWO2025141532A1Aerosol deliveryPharmaceutical non-active ingredientsPatient complianceTreatment options
This invention describes a novel, stable, fixed-dose, aqueous suspension of Amoxicillin Clavulanate for nasal administration to treat post-surgical nasal infections. The formulation leverages a unique combination of excipients, including mucoadhesive agents like chitosan, to enhance drug delivery and efficacy. Key features include targeted delivery to the infection site, sustained release for reduced dosing frequency, and the ability to disrupt bacterial biofilms. This innovative approach addresses the limitations of current treatment options by providing effective local drug delivery, minimizing systemic side effects, and improving patient compliance.
Owner:AODH LIFESCI PTE LTD
Dissolvable orally adhering nicotine tablet
PCT designated stage expiredWO2025011726A1Organic active ingredientsUnknown materialsAlcohol sugarsMucoadhesion
A dissolvable orally adhering nicotine tablet for sustained delivery of nicotine is disclosed, the tablet is a multilayer tablet comprising a first layer and a second layer, wherein the first layer is a mucoadhesive layer comprising a mucoadhesive, nicotine, and at least one sugar alcohol, and wherein the second layer comprises at least one sugar alcohol.
Owner:FERTIN PHARMA AS
Mucoadhesive microgel compositions and methods for using the same
Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.
Owner:CENT NAT DE LA RECH SCI (C N R S) +1
Film delivery system with perforations
The present invention relates to a film delivery system comprising a mucoadhesive layer, wherein the mucoadhesive layer comprises a film-forming agent and is provided with perforations.
Owner:LTS LOHMANN THERAPIE SYST AG
Mucoadhesive-PLGA nanoparticles
The present invention relates to a non-injectable drug delivery system using mucoadhesive nanoparticles, and to mucoadhesive nanoparticles and a method for producing the same, which prevent deformation of the nanoparticles due to mucosal moisture, etc., and strengthen mucoadhesiveness to prevent loss by binding a mucoadhesive polymer to the surface of the nanoparticles. The present invention also relates to a composition for maturing antigen-presenting cells, a composition for treating infectious diseases, and a composition for treating cancer, which comprise the mucoadhesive nanoparticles. The present invention also relates to mucoadhesive nanoparticles loaded with immune active substances (such as antigens and adjuvants) for cancer treatment and immunotherapy based on antigen-presenting cells including dendritic cells (DCs), and a composition for immune anti-cancer treatment comprising the same.
Owner:プレスティージ バイオファーマ アイディーシー カンパニー リミテッド +1
Formulations comprising seletracetam and methods of use
Provided herein are methods of treating a seizure disorder in a subject in need thereof comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Also provided are methods of treating a pain, neurological, or psychiatric disorder, and methods of administering seletracetam to a subject comprising administering seletracetam to the subject intranasally, buccally, or sublingually. Various pharmaceutical formulations comprising seletracetam, e.g., an orally disintegrating tablet and a mucoadhesive film, and a nasal spray device or oromucosal spray device comprising seletracetam are also provided.
Owner:PREVEP LLC
Compositions and methods for preventing the spread of viruses
PCT designated stageWO2026030503A3Peptide/protein ingredientsImmunoglobulins against virusesChimera ProteinViral infection
The present application relates to compositions and methods for: (a) preventing or treating viral infections; and / or (b) preventing the transmission and / or spread of infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a virus, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating viral infections, preventing the transmission of a viral infection from an infected individual to a non-infected individual, and for preventing the spread of a viral infection within a population of individuals.
Owner:INVISISHIELD TECHNOLOGIES LTD +6
Methods of treating treatment resistant depression
PCT designated stageWO2026030301A1Nervous disorderPharmaceutical delivery mechanismDosing regimenRegimen
The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.
Owner:ATAI THERAPEUTICS INC
Compounds for use in the treatment of positive symptoms in schizophrenia
PendingGB2635787AOrganic active ingredientsNervous disorderSustained Release TabletPharmaceutical medicine
Formula I Provided is 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazol-8-yl)benzonitrile of Formula I, also known as CF3CN, for use in the treatment of positive symptoms of schizophreni
Owner:ONTRACK THERAPEUTICS LTD
Modified carboxymethyl cellulose, their compositions and the uses thereof
Disclosed is a modified carboxylated polysaccharide, more particularly a modified carboxymethyl cellulose (CMC) functionalized with at least one mono-valent (M+) cation and at least one di-valent (M++) cation. Further disclosed herein is a mucoadhesive composition comprising the modified carboxymethyl cellulose (CMC) functionalized with at least one mono-valent (M+) cation and at least one di-valent (M++) cation. Further disclosed is application of the mucoadhesive composition in denture adhesives and toothpaste compositions.
Owner:ISP INVESTMENTS LLC
ORAL CODELIVERY OF 5-FLUOREURACIL AND Bcl2 siRNA TREATING STOMACH CANCER
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
BIFUNCTIONAL PEPTIDE WITH MUCOADHESIVE AND VIRUS-BINDING PROPERTIES
Owner:FORSCHUNGSVERBUND BERLIN EV +1
Method for preparing an active layer and apparatus comprising the active layer
The present disclosure relates to methods for preparing an active layer, typically a layer comprising a mucoadhesive material and one or more pharmaceutically active compounds or nutrients, and devices comprising such active layers. The method is designed to maintain the mucoadhesive material in a non-activated form during the preparation of the active layer and to allow the mucoadhesive material to be activated once near the target site.
Owner:TULIP MEDICAL LTD
Mucoadhesive pharmaceutical compositions of corticosteroids
Described herein are mucoadhesive pharmaceutical compositions of corticosteroids, as well as methods of making such pharmaceutical compositions, and therapeutic methods using them. The compositions typically comprise a corticosteroid in a mucoadhesive system, wherein the mucoadhesive system comprises a rheology-modifying agent and a vehicle for the corticosteroid. The compositions are particularly useful for treating inflammatory conditions of the esophagus, such as eosinophilic esophagitis, or inflammatory bowel disease.
Owner:FERRING BV
Applicator for arranging mucoadhesive surface on nasal or oral mucosa of patient and disposable component for use therewith
The present invention relates to an applicator (100) for arranging a mucoadhesive surface (202), in particular a mucoadhesive film (204) loaded with an active agent (e.g., a drug), on the nasal or oral mucosa, in particular buccal mucosa of a patient, the invention also relates to a disposable component for use with an applicator for arranging a mucoadhesive surface on a nasal mucosa or oral mucosa of a patient, and to a kit, the kit includes a disposable component having a mucoadhesive surface and an applicator for disposing the mucoadhesive surface on a nasal or oral mucosa of a patient.
Owner:IQ MEDICAL CO LTD
Mucoadhesive oral tablet for symptomatic treatment of xerostomia, mouth ulcers and inflammations of the oral cavity
Disclosed are formulations in the form of mucoadhesive tablets useful for treating symptoms caused by xerostomia (dry mouth). The tablets according to the invention comprise hyaluronic acid, choline alfoscerate and ascorbyl palmitate, and are characterised by two concave surfaces that adapt to the oral and gingival mucosa so as to adhere to the oral vestibules or the palate.
Owner:RICERFARMA